SCM
Stonepine Capital Management Portfolio holdings
AUM
$102M
This Quarter Return
+31.91%
1 Year Return
+40.04%
3 Year Return
+160.28%
5 Year Return
+195.28%
10 Year Return
–
AUM
$158M
AUM Growth
+$158M
(+44%)
Cap. Flow
+$12.5M
Cap. Flow
% of AUM
7.92%
Top 10 Holdings %
Top 10 Hldgs %
69.15%
Holding
41
New
16
Increased
13
Reduced
5
Closed
3
Top Buys
| 1 |
Jazz Pharmaceuticals
JAZZ
|
$6.13M |
| 2 |
Royalty Pharma
RPRX
|
$6M |
| 3 |
Zevra Therapeutics
ZVRA
|
$4.86M |
| 4 |
Ironwood Pharmaceuticals
IRWD
|
$3.92M |
| 5 |
Verastem
VSTM
|
$3.92M |
Top Sells
| 1 |
ALIM
Alimera Sciences, Inc.
ALIM
|
$19.5M |
| 2 |
RVNC
Revance Therapeutics, Inc.
RVNC
|
$10.3M |
| 3 |
Evolus
EOLS
|
$4.66M |
| 4 |
Aurinia Pharmaceuticals
AUPH
|
$1.71M |
| 5 |
Xoma
XOMA
|
$1.46M |
Sector Composition
| 1 | Healthcare | 99.94% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Shares Change % | Capital Flow | |
|---|---|---|---|---|---|---|
1
ADMA Biologics
ADMA
$4.12B
| $37.4M | 23.62% |
1,870,000
| – | – |
|
|
2
Evolus
EOLS
$494M
| $22.2M | 14.02% |
1,369,821
-287,790
| -17% | -$4.66M |
|
3
Galapagos
GLPG
$2.07B
| $13.8M | 8.71% |
478,659
-6,341
| -1% | -$183K |
|
|
4
Jazz Pharmaceuticals
JAZZ
$7.75B
| $6.13M | 3.87% |
+55,000
| New | +$6.13M |
|
|
5
Royalty Pharma
RPRX
$15.6B
| $6M | 3.79% |
+212,000
| New | +$6M |
|
|
6
Xoma
XOMA
$392M
| $5.17M | 3.26% |
195,096
-55,033
| -22% | -$1.46M |
|
7
Rigel Pharmaceuticals
RIGL
$697M
| $5M | 3.16% |
309,100
+4,100
| +1% | +$66.3K |
|
|
8
Zevra Therapeutics
ZVRA
$509M
| $4.86M | 3.07% |
+700,000
| New | +$4.86M |
|
9
Anika Therapeutics
ANIK
$135M
| $4.68M | 2.95% |
189,308
+23,911
| +14% | +$591K |
|
|
RVNC
10
DELISTED
Revance Therapeutics, Inc.
RVNC
| $4.26M | 2.69% |
820,000
-1,980,000
| -71% | -$10.3M |
|
|
11
Ironwood Pharmaceuticals
IRWD
$214M
| $4.12M | 2.6% |
1,000,000
+951,988
| +1,983% | +$3.92M |
|
|
12
Verastem
VSTM
$569M
| $3.92M | 2.48% |
+1,310,287
| New | +$3.92M |
|
|
OPTN
13
DELISTED
OptiNose
OPTN
| $3.81M | 2.41% |
5,688,590
+3,338,580
| +142% | +$2.24M |
|
14
UroGen Pharma
URGN
$900M
| $3.56M | 2.25% |
+280,345
| New | +$3.56M |
|
15
scPharmaceuticals
SCPH
$295M
| $3.55M | 2.24% |
778,874
+357,171
| +85% | +$1.63M |
|
16
Establishment Labs
ESTA
$1.2B
| $3.25M | 2.05% |
+75,000
| New | +$3.25M |
|
17
Acadia Pharmaceuticals
ACAD
$4.38B
| $3.03M | 1.91% |
196,895
+191,895
| +3,838% | +$2.95M |
|
18
Day One Biopharmaceuticals
DAWN
$769M
| $2.87M | 1.81% |
+205,675
| New | +$2.87M |
|
19
Aclaris Therapeutics
ACRS
$209M
| $2.83M | 1.79% |
2,458,873
+531,427
| +28% | +$611K |
|
20
TELA Bio
TELA
$70.5M
| $2.81M | 1.77% |
1,110,000
+484,355
| +77% | +$1.23M |
|
21
Indivior
INDV
$3.03B
| $2.63M | 1.66% |
+270,000
| New | +$2.63M |
|
22
Exagen
XGN
$217M
| $1.65M | 1.04% |
534,398
+175,701
| +49% | +$543K |
|
23
Milestone Pharmaceuticals
MIST
$156M
| $1.52M | 0.96% |
999,790
-239,409
| -19% | -$364K |
|
24
Surrozen
SRZN
$104M
| $1.32M | 0.83% |
110,000
+43,916
| +66% | +$526K |
|
25
AYTU BioPharma
AYTU
$21.1M
| $1.18M | 0.74% |
500,958
+28,489
| +6% | +$66.9K |
|